Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0011359C (M7824) in Subjects With Metastatic or Locally Advanced Solid Tumors With Expansion to Selected Indications in Asia

Trial Profile

A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0011359C (M7824) in Subjects With Metastatic or Locally Advanced Solid Tumors With Expansion to Selected Indications in Asia

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 26 Sep 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bintrafusp alfa (Primary)
  • Indications Adenocarcinoma; Adenoid cystic carcinoma; Biliary cancer; Carcinoma; Colon cancer; Colorectal cancer; Gastric cancer; Liver cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Parotid cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Tongue cancer; Vulvovaginal cancer
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline; GSK; Merck KGaA
  • Most Recent Events

    • 26 Sep 2022 Results deriving PK and AE data from studies NCT02517398, NCT02699515, NCT03840915, and NCT04246489; describing a model-informed dose modification approach for risk management of Bintrafusp alfa associated bleeding adverse events, published in the Cancer Chemotherapy and Pharmacology
    • 07 Mar 2022 Status changed from active, no longer recruiting to completed.
    • 11 Apr 2021 Results (at data cutoff: 24 August 2018; n=30) of phase 1 cohort, published in the Targeted Oncology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top